Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#4656 Development of a 3D patient-derived extracellular matrix hydrogel model of small intestinal neuroendocrine tumour and mesenteric fibrosis

Introduction: The pathogenesis of mesenteric fibrosis in small intestinal neuroendocrine tumours (SI-NETs) is poorly understood, limiting development of effective treatments and biomarkers. A major barrier to research is the lack of disease models.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Luong T, Hall A, Webster A,

Keywords: small intestine, neuroendocrine, 3D model, hydrogel, fibrosis,

#4642 Establishing a standardised histopathological grading system for mesenteric fibrosis in small intestinal neuroendocrine tumours

Introduction: Mesenteric fibrosis (MF) frequently develops around mesenteric metastasis in small intestinal neuroendocrine tumour (SI-NET) patients. Since MF is not always detected radiologically, histopathological examination is considered the gold standard. However, there is no uniform histopathological scoring system for MF correlated with clinical data.

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, Hofland L, Hall A, Iyer A,

Keywords: small intestinal neuroendocrine tumour, mesenteric fibrosis, grading system,

#4632 MEN1 associated pancreatic neuroendocrine tumours: Re-evaluating the 2cm cut-off for surgical resection

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are the leading cause of death in patients (pts) with MEN1. Screening is recommended to diagnose early and prevent metastases. The optimal cut-off of when to intervene in a PanNET is still an area of debate.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: MEN1, Pan NET,

#4619 Targeted beta- plus auger and conversion electron therapy with terbium-161 labelled somatostatin receptor antagonist DOTA-LM3 – BETA plus phase 0 study

Introduction: Radioligand therapy with lutetium-177 labelled somatostatin receptor (SSTR) agonists (177Lu-DOTATATE or 177Lu-DOTATOC) showed limited response rate and durability. The novel SSTR antagonist DOTA-LM3 labelled with terbium-161, which co-emits conversion and Auger electrons in addition to β- particles, potentially increasing tumour doses and offering a more effective treatment for micro metastases.

Conference:

Presenting Author: Fricke J

Authors: Fricke J, Westerbergh F, McDougall L, Christ E, Nicolas G,

Keywords: Radionuclide therapy, PRRT, Auger electrons, Conversion electrons, Terbium-161, radiolabelled somatostatin antagonist, neuroendocrine tumour,